Provide our clients with tailored cell and gene therapy solutions, including proprietary genome editing, unparalleled iPSC expertise, and high-quality manufacturing services.
Rejuvenating lives through accessible, innovative cell & gene products
The "ASC DNA"
Innovation
- Imaginative for impactful solutions
- Cutting-edge technology to revolutionize our industry
Passion
- Believe in our vision and mission to achieve goals, ours and our clients’
- Take ownership, be accountable and enthusiastic with unwavering dedication
Smarts
- Provide unparalleled technical experience with innovative technologies
- Ability to see things in new and insightful ways
Collaboration
- Open communication
- Respect everyone with mutual understanding
Social Responsibility
- Stay true to our vision of rejuvenating lives
- Mindful of how our work impacts the world
cGMP Grade iPSC Line & GMP CDMO Services
ASC’s new GMP room is certified and fully equipped for iPSC/MSC-derived product development and cell manufacturing.
GMP CDMO Services
- cGMP iPSC Expansion & Banking
- Customized iPSC Generation (Episomal Method)
- iPSC Gene Editing: TCRISPR/Cas9 Editing
- iPSC Gene Editing: TARGATT Gene Editing
- In-Process QC (Reagent QC (plasmid map/sequence), Validation (cell, gRNA, integrase), and more)
- iPSC Differentiation: Customer Provide Protocol
- iPSC Differentiation: ASC’
GMP Grade iPSC Line
- Drug master file with US FDA
- Master cell bank and working cell bank
Certifications
NIST
Member
200+
Biotech,
Cell Therapy,
Pharma Clients
1000+
Customers
Patented Technology Underscores Differentiated CRDMO Offerings
- 15+ unique patents filed with 5 gene editing patents granted
- CRISPR/Cas technology licensed from MIT/Broad and UC Berkeley/ERS Genomics.
- iPSC technology licensed from iPS Academia, Japan
Unique Site-Specific Technology TARGATT™ Licensable for Cell Therapy Applications
- >30 TARGATTTM license agreements have been executed to companies.
- License-out-ready cell lines
Applied StemCell’s technology and scientific experience has enabled a successful gene therapy pipeline for intractable monogenic disorders, and the formation of our sister company, ASC Therapeutics (ASCTx) under the Applied StemCell, Inc corporate umbrella. Under the leadership of Dr. Ruby Chen-Tsai who spearheaded the former therapeutics program, Applied StemCell’s mission as a gene and cell therapy CRO will benefit the advancement of safer and effective gene and cell therapy programs with collaborators in the biotechnology industry.